Most of the 304 study participants were male (90.5%) and a majority (60.9%) were at least 50 years old (Table 1). Almost one-half (45.4%) screened positive for depression (PHQ-9 ≥ 10), nearly one-third (30.3%) screened positive for generalized anxiety (GAD ≥ 10) and the same proportion (30.3%) screened positive for PTSD (PCL ≥ 50). About one in 10 (9.5%) had symptoms consistent with DSM-IV panic disorder, while nearly one-fifth (18.8%) met criteria for a past year DSM-IV drug use disorder.Table 1Characteristics of study population: VA primary care patients enrolled in the CHOICE trial (n = 304)n(%)Female29(9.5)Age categories 21–3454(17.8) 35–4965(21.4) 50–64131(43.1) 65+54(17.8)Patient-reported race Native American25(8.2) Asian2(0.7) Native Hawaiian/Pacific Islander5(1.6) Black39(12.8) White206(67.8) Multiracial22(7.2) Other5(1.6) Hispanic/Latino21(6.9)Marital status Never married56(18.4) Married/partnered136(44.7) Separated13(4.3) Divorced91(29.9) Widowed7(2.3) Refused/unknown1(0.3)Education High school/GED or less65(21.4) Some college/tech school170(55.9) College or post graduate69(22.7)Income <$15,00049(16.1) $15,000-59,999158(52.0) ≥$60,00095(31.3) Refused/Unknown2(0.7)Smokes tobacco currently134(44.1)Depression screen positive (PHQ-9 ≥ 10)138(45.4)Generalized anxiety screen positive (GAD-7 ≥ 10)92(30.3)PTSD screen positive (PCL-C ≥ 50)a 91(30.3)DSM-IV panic disorder– current (MINI)29(9.5)DSM-IV drug use disorders past year (MINI)57(18.8) aFour patients did not complete the PCL
